The review commissioned by Britain’s Treasury was hailed by some environmentalists but one prominent climate activist slammed its “natural capital agenda” for putting a price tag on nature.
Daniel Farber says the most consequential phase of the high-stakes litigation may be during discovery; when the companies make disclosures that could reach the public.
The most that Paul Hockenos expects from the new administration’s foreign policy is some tinkering around the edges.
In marking the anniversary of the Egyptian uprising, it is deceptive to celebrate a revolution. The word “revolution” has been bandied about a lot since 2011, writes As’ad AbuKhalil.
The staggering concentration of wealth at the top has deformed our governing institutions. New window dressing will not end oligarchy.
Almost unknown in the U.S., Hajjar heckled Ben-Gurion, joined the civil rights movement in the South, and lost his job with the PLO for allegedly insulting Arafat.
“Instead of spending on innovation, Big Pharma is hoarding its money for salaries and dividends,” the report says, “all while swallowing smaller companies, thus making the marketplace far less competitive.”